TC
GHDX

TFS Capital’s Genomic Health, Inc. GHDX Stock Holding History

TFS Capital’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-27,798
Closed -$905K – 511
2017
Q2 		$905K Sell
27,798
-7,228
-21% -$229K 0.35% 63
2017
Q1 		$1.1M Sell
35,026
-19,032
-35% -$563K 0.36% 74
2016
Q4 		$1.59M Sell
54,058
-11,028
-17% -$336K 0.42% 27
2016
Q3 		$1.88M Buy
65,086
+3,313
+5% +$92.3K 0.45% 18
2016
Q2 		$1.6M Sell
61,773
-23,322
-27% -$619K 0.29% 54
2016
Q1 		$2.11M Buy
85,095
+22,873
+37% +$628K 0.3% 50
2015
Q4 		$2.19M Sell
62,222
-121,522
-66% -$3.25M 0.24% 146
2015
Q3 		$3.89M Buy
183,744
+81,263
+79% +$2.09M 0.37% 51
2015
Q2 		$2.85M Buy
102,481
+81,751
+394% +$2.31M 0.28% 81
2015
Q1 		$633K Buy
20,730
+2,132
+11% +$67.8K 0.06% 476
2014
Q4 		$595K Sell
18,598
-2,307
-11% -$75.1K 0.06% 530
2014
Q3 		$592K Buy
20,905
+8,319
+66% +$232K 0.05% 540
2014
Q2 		$345K Buy
+12,586
New +$335K 0.03% 784

Other funds holding GHDX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

TFS Capital's GHDX Position: Q3 2017 in Review

TFS Capital sold out of Genomic Health, Inc. (GHDX) in Q3 2017, closing a stake of 27,798 shares — an estimated $905K sold.

TFS Capital first reported a position in GHDX in Q2 2014 and held it in 13 quarters. The position peaked at $3.89M in Q3 2015. 134 funds tracked by Wall St. Rank hold GHDX as of Q3 2017.

  • TFS Capital reported no remaining Genomic Health, Inc. position as of Q3 2017 after selling out during the quarter.
  • TFS Capital sold 27,798 Genomic Health, Inc. shares in Q3 2017, an estimated $905K.
  • TFS Capital first reported a position in Genomic Health, Inc. in Q2 2014 and held it in 13 quarters.
  • TFS Capital's Genomic Health, Inc. position peaked at $3.89M in Q3 2015.
  • 134 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.